image
Healthcare - Biotechnology - NASDAQ - US
$ 2.44
-5.47 %
$ 93.5 M
Market Cap
-1.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one OBIO stock under the worst case scenario is HIDDEN Compared to the current market price of 2.44 USD, Orchestra BioMed Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one OBIO stock under the base case scenario is HIDDEN Compared to the current market price of 2.44 USD, Orchestra BioMed Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one OBIO stock under the best case scenario is HIDDEN Compared to the current market price of 2.44 USD, Orchestra BioMed Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OBIO

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
2.64 M REVENUE
-4.42%
-64.3 M OPERATING INCOME
-24.84%
-61 M NET INCOME
-24.23%
-50.6 M OPERATING CASH FLOW
-9.61%
13.1 M INVESTING CASH FLOW
22.48%
29.2 M FINANCING CASH FLOW
-36.88%
253 K REVENUE
-74.37%
-16.7 M OPERATING INCOME
-2.05%
-16.2 M NET INCOME
-4.73%
-13.5 M OPERATING CASH FLOW
1.18%
-3.75 M INVESTING CASH FLOW
-673.79%
13.9 M FINANCING CASH FLOW
-7.24%
Balance Sheet Orchestra BioMed Holdings, Inc.
image
Current Assets 69.2 M
Cash & Short-Term Investments 66.8 M
Receivables 92 K
Other Current Assets 2.27 M
Non-Current Assets 7 M
Long-Term Investments 2.5 M
PP&E 3.49 M
Other Non-Current Assets 1.02 M
87.71 %2.98 %3.28 %4.58 %Total Assets$76.2m
Current Liabilities 16.2 M
Accounts Payable 5.13 M
Short-Term Debt 550 K
Other Current Liabilities 10.5 M
Non-Current Liabilities 27 M
Long-Term Debt 14.3 M
Other Non-Current Liabilities 12.7 M
11.88 %24.35 %33.07 %29.42 %Total Liabilities$43.2m
EFFICIENCY
Earnings Waterfall Orchestra BioMed Holdings, Inc.
image
Revenue 2.64 M
Cost Of Revenue 204 K
Gross Profit 2.43 M
Operating Expenses 66.7 M
Operating Income -64.3 M
Other Expenses -3.28 M
Net Income -61 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)3m(204k)2m(67m)(64m)3m(61m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.27% GROSS MARGIN
92.27%
-2437.49% OPERATING MARGIN
-2437.49%
-2313.27% NET MARGIN
-2313.27%
-185.16% ROE
-185.16%
-80.11% ROA
-80.11%
-106.25% ROIC
-106.25%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Orchestra BioMed Holdings, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -61 M
Depreciation & Amortization 308 K
Capital Expenditures -289 K
Stock-Based Compensation 10.6 M
Change in Working Capital -765 K
Others -3.42 M
Free Cash Flow -50.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Orchestra BioMed Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for OBIO of $12 , with forecasts ranging from a low of $12 to a high of $12 .
OBIO Lowest Price Target Wall Street Target
12 USD 391.80%
OBIO Average Price Target Wall Street Target
12 USD 391.80%
OBIO Highest Price Target Wall Street Target
12 USD 391.80%
Price
Max Price Target
Min Price Target
Average Price Target
1212111110109988776655443322Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Orchestra BioMed Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
226 K USD 2
9-12 MONTHS
0 USD 0
Bought
276 K USD 1
0-3 MONTHS
48 K USD 2
3-6 MONTHS
47.9 K USD 1
6-9 MONTHS
74.5 K USD 2
9-12 MONTHS
7. News
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure NEW HOPE, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced continued expansion of its global intellectual property (IP) estate supporting its proprietary AVIM therapy pipeline (formerly known as Cardiac Neuromodulation Therapy or “CNT”). Over the past 12 months, the Company has secured 10 new patents related to treatment of hypertension. The Company has also secured a total of 17 patents covering application of the technology for treatment of heart failure, significantly expanding the reach of its IP platform. globenewswire.com - 1 week ago
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon Orchestra BioMed's Virtue ® Sirolimus AngioInfusion Balloon™   (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis (“ISR”) Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025 NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Investigational Device Exemption (“IDE”) amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial (“Virtue Trial”). globenewswire.com - 3 weeks ago
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. globenewswire.com - 3 weeks ago
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company's atrioventricular interval modulation (“AVIM”) therapy program. globenewswire.com - 3 weeks ago
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy. globenewswire.com - 4 weeks ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago. zacks.com - 1 month ago
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. globenewswire.com - 1 month ago
Orchestra BioMed to Present at Upcoming Investor Conferences NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences. globenewswire.com - 2 months ago
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio. globenewswire.com - 3 months ago
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients. globenewswire.com - 3 months ago
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach. globenewswire.com - 3 months ago
8. Profile Summary

Orchestra BioMed Holdings, Inc. OBIO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 93.5 M
Dividend Yield 0.00%
Description Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Contact 150 Union Square Drive, New Hope, PA, 18938 https://orchestrabiomed.com
IPO Date Aug. 4, 2020
Employees 70
Officers Dr. Hans-Peter Stoll M.D., Ph.D. Chief Clinical Officer Mr. Darren R. Sherman Founder, President, Chief Operating Officer & Director Mr. Bob Laughner Senior Vice President of Regulatory & Quality Mr. Andrew Lawrence Taylor M.B.A. Chief Financial Officer Dr. Yuval Hay Mika D.Sc, Ph.D. GM & Chief Technology Officer of Bioelectronic Therapies Dr. Avraham Matityahu Fischer M.D. Senior Vice President of Medical Affairs & Innovation Mr. Juan Lorenzo Senior Vice President of Product Development Mr. William Reed Little Executive Vice President of Corporate Development & Strategy Mr. Mark Pomeranz GM & Executive Vice President of Interventional Therapies Mr. David P. Hochman Founder, Chairman of the Board of Directors & Chief Executive Officer